Needham & Company LLC Reaffirms Buy Rating for Taysha Gene Therapies (NASDAQ:TSHA)
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report)‘s stock had its “buy” rating reiterated by Needham & Company LLC in a note issued to investors on Monday,Benzinga reports. They presently have a $8.00 price objective on the stock, up from their prior price objective of $6.00. Needham & Company LLC’s price target indicates a potential […]
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report)‘s stock had its “buy” rating reiterated by Needham & Company LLC in a note issued to investors on Monday,Benzinga reports. They presently have a $8.00 price objective on the stock, up from their prior price objective of $6.00. Needham & Company LLC’s price target indicates a potential […]
